Korro Bio is a biotechnology company focused on developing novel gene editing technologies to advance precision medicine and transform the treatment of genetic diseases. Founded in 2018, Korro Bio's innovative approaches have the potential to revolutionize the field of genetic medicine and bring about new therapeutic solutions for patients worldwide.

Director, Toxicology

Director, Analytical Development - Oligonucleotide

Associate Director of Manufacturing Sciences

Associate Scientist, Disease Area Biology

Senior Director, Clinical Development

Associate Director/Director, Quality Assurance

SEC Reporting Manager

Senior Manager, Strategy and Portfolio Planning

RNA Therapeutics Scientist

<div><b>Company Summary:</b>&nbsp;<span style="font-size: 11pt">Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha-1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts. </span></div><div><br></div><div><span style="font-size: 11pt">We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - </span><i style="font-size: 11pt">Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity </i><span style="font-size: 11pt">form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.</span></div>

Director, Clinical Assay Development & Biomarkers

<div><b>Company Summary:</b>&nbsp;<span style="font-size: 11pt">Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha-1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts. </span></div><div><br></div><div><span style="font-size: 11pt">We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - </span><i style="font-size: 11pt">Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity </i><span style="font-size: 11pt">form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.</span></div><div><br></div><div><b style="font-size: 11pt;">Position Summary:</b></div><div><span style="font-size: 10pt;">We are seeking an experienced and strategic </span><b style="font-size: 10pt;">Senior Scientist, Machine Learning</b><span style="font-size: 10pt;"> to drive the development and application of machine learning solutions for genetic medicine discovery and development. This role offers the opportunity to apply deep learning and statistical methods in current and novel areas across our RNA editing platform, from target identification and oligonucleotide design to patient stratification and clinical optimization.</span></div><div><span style="font-size: 10pt;">&nbsp;</span></div><div><span style="font-size: 10pt;">The ideal candidate will bring deep expertise in both machine learning and statistics, enabling rigorous experimental design, hypothesis testing, and model validation in complex biological systems. You will have significant autonomy to identify and explore new applications of ML/AI across diverse functions within the organization, working at the intersection of computational biology, drug discovery, and precision medicine.</span></div><div><br></div><div><br></div><div><br></div>

Senior Scientist, Machine Learning (Drug Development)

<div><b>Company Summary:</b>&nbsp;<span style="font-size: 11pt">Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha-1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts. </span></div><div><br></div><div><span style="font-size: 11pt">We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - </span><i style="font-size: 11pt">Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity </i><span style="font-size: 11pt">form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.</span></div><div><br></div><div><b style="font-size: 16px;">Position Summary:</b></div><div><span style="font-size: 16px;">&nbsp;</span></div><div><span style="font-size: 16px;">We are seeking an experienced clinical development physician to lead one or more clinical programs at Korro. In this highly visible role reporting to the Chief Medical Officer, you will drive clinical development related activities for Korro’s lead program in Alpha-1 Antitrypsin Deficiency (AATD), as well as additional pipeline programs. This is an onsite role in Cambridge, Massachusetts, with a requirement to be in the office 3 days a week.</span></div><div><span style="font-size: 16px;">Excellent written and oral communication skills are required, as is the desire and ability to work in a small, fast-paced, and patient-focused environment.</span></div>

<div><b>Company Summary:</b>&nbsp;<span style="font-size: 11pt">Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha-1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts. </span></div><div><br></div><div><span style="font-size: 11pt">We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - </span><i style="font-size: 11pt">Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity </i><span style="font-size: 11pt">form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.</span></div><div><br></div><div><b>Position Summary:</b></div><div>Korro Bio&nbsp;is&nbsp;seeking a Director of Process Development to join the growing CMC (Chemistry, Manufacturing, and Controls) team. You will play a critical role in developing and optimizing manufacturing processes for our oligonucleotide-based Therapeutics. This role requires a deep understanding of process development, scale-up, and technology transfer for drug substance as well as cross-functional collaboration with internal and external partners. You will lead a team of scientists and engineers to ensure the scalability, efficiency, and regulatory compliance of our therapeutic development.</div>

Director, Process Development

<div><b>Company Summary:</b>&nbsp;<span style="font-size: 11pt">Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is Alpha-1 Antitrypsin Deficiency (AATD). Korro is based in Cambridge, Massachusetts. </span></div><div><br></div><div><span style="font-size: 11pt">We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - </span><i style="font-size: 11pt">Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity </i><span style="font-size: 11pt">form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.</span></div><div><br></div><div><b>Position Summary:</b></div><div>Korro Bio is seeking a highly motivated Senior Director of Toxicology to lead the design and execution of nonclinical safety studies across our RNA editing portfolio. Reporting to the VP of Research and Preclinical, this individual will be a key scientific and strategic contributor responsible for building and advancing Korro’s toxicology capabilities, with an emphasis on oligonucleotide-based therapeutics. The ideal candidate brings deep experience in nonclinical development, a collaborative mindset, and a passion for bringing novel genetic medicines to patients.</div>

Get a job referral to Korro Bio

Your career is worth investing in.

Get unlimited referrals with Premium.